Patents by Inventor Mark Welch

Mark Welch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220282260
    Abstract: The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.
    Type: Application
    Filed: May 18, 2022
    Publication date: September 8, 2022
    Inventors: Jeremy Minshull, Mark Welch, Sridhar Govindrajan, Maggie Lee, Kate Caves, Jon Ness
  • Publication number: 20220145344
    Abstract: This disclosure provides epimerase enzymes useful for commercial scale production of allulose from fructose. The disclosed enzymes (“epimerase variants”) are variants of Burkholderia multivorans CGD1 xylose isomerase engineered to have improved catalytic activity of about 1.5- to 2-fold compared with the parent enzyme.
    Type: Application
    Filed: August 7, 2019
    Publication date: May 12, 2022
    Applicant: Archer Daniels Midland Company
    Inventors: William Schroeder, Padmesh Venkitasubramanian, Sridhar Govindarajan, Mark Welch
  • Publication number: 20220089762
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Application
    Filed: October 25, 2021
    Publication date: March 24, 2022
    Inventors: Michael SKOV, Tarlochan S. NIJJAR, Sridhar GOVINDARAJAN, Tom PURCELL, Mark WELCH, Frédérique BARD, Robin BARBOUR, Wagner ZAGO
  • Publication number: 20220049009
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Application
    Filed: July 23, 2021
    Publication date: February 17, 2022
    Inventors: Michael SKOV, Tarlochan S. NIJJAR, Sridhar GOVINDARAJAN, Tom PURCELL, Mark WELCH, Frédérique BARD, Robin BARBOUR, Wagner ZAGO
  • Publication number: 20220041701
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Application
    Filed: October 25, 2021
    Publication date: February 10, 2022
    Inventors: Michael SKOV, Tarlochan S. NIJJAR, Sridhar GOVINDARAJAN, Tom PURCELL, Mark WELCH, Frédérique BARD, Robin BARBOUR, Wagner ZAGO
  • Publication number: 20220041699
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Application
    Filed: October 25, 2021
    Publication date: February 10, 2022
    Inventors: Michael SKOV, Tarlochan S. NIJJAR, Sridhar GOVINDARAJAN, Tom PURCELL, Mark WELCH, Frédérique BARD, Robin BARBOUR, Wagner ZAGO
  • Publication number: 20220041700
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Application
    Filed: October 25, 2021
    Publication date: February 10, 2022
    Inventors: Michael SKOV, Tarlochan S. NIJJAR, Sridhar GOVINDARAJAN, Tom PURCELL, Mark WELCH, Frédérique BARD, Robin BARBOUR, Wagner ZAGO
  • Patent number: 11041159
    Abstract: The present disclosure provides nucleic acids and vectors for use with methanotrophic bacteria. Related host cells and methods for using such nucleic acids and vectors for expressing polypeptides or other genetic manipulation of methanotrophic bacteria are also provided.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: June 22, 2021
    Assignee: Calysta, Inc.
    Inventors: Renee M. Saville, Joshua Silverman, Jeremy Minshull, Jon Edward Ness, Effendi Leonard, Jana Stumpe, Mark Welch
  • Publication number: 20210139919
    Abstract: The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.
    Type: Application
    Filed: January 15, 2021
    Publication date: May 13, 2021
    Applicant: DNA TWOPOINTO INC.
    Inventors: Jeremy Minshull, Mark Welch, Sridhar Govindrajan, Maggie Lee, Kate Caves, Jon Ness
  • Patent number: 10927384
    Abstract: The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: February 23, 2021
    Assignee: DNA TWOPOINTO INC.
    Inventors: Jeremy Minshull, Mark Welch, Sridhar Govindrajan, Maggie Lee, Kate Caves, Jon Ness
  • Patent number: 10815461
    Abstract: Disclosed are recombinant mutant Candida utilis uricase enzymes with improved pancreatin stability and/or activity, compositions containing such uricase enzymes, which can be used, among other things, to treat diseases or disorders associated with an elevated amount of uric acid, including, for example, hyperuricemia, hyperuricosuria, and gout.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: October 27, 2020
    Assignee: Allena Pharmaceuticals, Inc.
    Inventors: Aditi R. Deshpande, Danica Grujic, Sridhar Govindarajan, Mark Welch
  • Publication number: 20200308534
    Abstract: Disclosed are recombinant mutant Candida utilis uricase enzymes with improved pancreatin stability and/or activity, compositions containing such uricase enzymes, which can be used, among other things, to treat diseases or disorders associated with an elevated amount of uric acid, including, for example, hyperuricemia, hyperuricosuria, and gout.
    Type: Application
    Filed: July 6, 2018
    Publication date: October 1, 2020
    Applicant: Allena Pharmaceuticals, Inc.
    Inventors: Aditi R. DESHPANDE, Danica GRUJIC, Sridhar GOVINDARAJAN, Mark WELCH
  • Publication number: 20200190524
    Abstract: The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.
    Type: Application
    Filed: December 23, 2019
    Publication date: June 18, 2020
    Applicant: DNA2.0, INC.
    Inventors: Jeremy Minshull, Mark Welch, Sridhar Govindrajan, Maggie Lee, Kate Caves, Jon Ness
  • Publication number: 20200071681
    Abstract: Disclosed are recombinant mutant Candida utilis uricase enzymes with improved pancreatin stability and/or activity, compositions containing such uricase enzymes, which can be used, among other things, to treat diseases or disorders associated with an elevated amount of uric acid, including, for example, hyperuricemia, hyperuricosuria, and gout.
    Type: Application
    Filed: November 5, 2019
    Publication date: March 5, 2020
    Inventors: Aditi R. Deshpande, Danica Grujic, Sridhar Govindarajan, Mark Welch
  • Publication number: 20200063146
    Abstract: The present disclosure provides nucleic acids and vectors for use with methanotrophic bacteria. Related host cells and methods for using such nucleic acids and vectors for expressing polypeptides or other genetic manipulation of methanotrophic bacteria are also provided.
    Type: Application
    Filed: August 28, 2019
    Publication date: February 27, 2020
    Inventors: Renee M. Saville, Joshua Silverman, Jeremy Minshull, Jon Edward Ness, Effendi Leonard, Jana Stumpe, Mark Welch
  • Patent number: 10480018
    Abstract: Disclosed herein are three geneses of proteins herein established to exhibit a fructose to allulose epimerase activity that are useful for production of allulose from fructose at high temperatures and at low pH in the range of 4.5 to 6.0. Two of the three geneses descend phylogenetically from a common ancestral protein defined herein, and these geneses are distinguished from each other by different parental descendant proteins also defined herein. The proteins with high levels of sequence identity to the parental nodes defining from these two geneses generally exhibit higher levels of specific fructose to glucose epimerase activity than prior known fructose to allulose epimerases and exhibit such activity at low pH. A third genus is not defined by phylogenetic origin except by not descending from the same ancestor as the first two geneses but generally exhibit similar levels of fructose to allulose epimerase activities as prior art epimerases described to be useful for fructose to allulose conversion.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: November 19, 2019
    Assignee: ARCHER DANIELS MIDLAND COMPANY
    Inventors: Padmesh Venkitasubramanian, William Schroeder, Mark Welch, Sridhar Govindarajan
  • Publication number: 20190323018
    Abstract: The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.
    Type: Application
    Filed: June 20, 2019
    Publication date: October 24, 2019
    Applicant: DNA2.0, INC.
    Inventors: Jeremy Minshull, Mark Welch, Sridhar Govindrajan, Maggie Lee, Kate Caves, Jon Ness
  • Patent number: 10443060
    Abstract: The present disclosure provides nucleic acids and vectors for use with methanotrophic bacteria. Related host cells and methods for using such nucleic acids and vectors for expressing polypeptides or other genetic manipulation of methanotrophic bacteria are also provided. In one aspect, the present disclosure is directed to a non-naturally occurring nucleic acid molecule, comprising (1) a promoter that is functional in a methanotrophic bacterium, and (2) a native or altered methanol dehydrogenase (MDH) ribosomal binding sequence, provided that when the promoter is an MDH gene promoter, the nucleic acid comprises an altered MDH ribosomal binding sequence.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: October 15, 2019
    Assignee: CALYSTA, INC.
    Inventors: Renee M. Saville, Joshua Silverman, Jeremy Minshull, Jon Edward Ness, Effendi Leonard, Jana Stumpe, Mark Welch
  • Patent number: 10346221
    Abstract: A method includes a processor for determining a life cycle of a first performance of a task flow for a telecommunication service order, determining that a performance of a first task within the first performance of the task flow has exceeded a threshold processing time, and determining that there is a problem with a first centralized system component in response to determining that the performance of the first task within the first performance of the task flow has exceeded the threshold processing time. The method may further include identifying the centralized system component for servicing when it is determined that there is a problem with the centralized system component.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: July 9, 2019
    Assignee: AT&T Intellectual Property I, L.P.
    Inventors: Arun Kandappan, Joseph Schutte, Mark Welch, Kevin White
  • Patent number: 10344285
    Abstract: The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: July 9, 2019
    Assignee: DNA2.0, INC.
    Inventors: Jeremy Minshull, Mark Welch, Sridhar Govindrajan, Maggie Lee, Kate Caves, Jon Ness